A Phase 4 interventional study of Stop current treatment (anti-HBV neucleos(t)ides) and Keep current treatment (anti-HBV neucleos(t)ides) in Chronic Hepatitis B, sponsored by Humanity & Health Medical Group Limited. Recruiting at 1 site in Hong Kong. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Humanity & Health Medical Group Limited · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Hepatitis B, Chronic with a site in Hong Kong — 8 open to participants now, 15 under way, none of them phase 3. Hepatitis B, Chronic · Hong Kong.
Among the 88 studies in Hepatitis B, Chronic with a site in Hong Kong, this one has the largest planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2018, is one of 11 in phase 4, reaches primary completion later than 2 of the 14 other live ones, and was the 47th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →8 of the 88 studies in Hepatitis B, Chronic with a site in Hong Kong are open now. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
Tune Therapeutics, Inc. · Sites in Hong Kong, Moldova, New Zealand
Ages 18–75
Precision BioSciences, Inc. · Sites in Hong Kong, United States, France and 3 more countries
Ages 18–70
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 34 · Phase 3 7 · Phase 4 11
First in 2000; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 79 interventional studies, 269 across the 9 observational. Of the 69 that completed or were terminated, 34 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 88 have an industry lead sponsor. The 10 most frequent:
Humanity & Health Medical Group Limited is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Humanity & Health Medical Group Limited has 1 study filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
5 of the studies in Hepatitis B, Chronic with a site in Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06680232Precision BioSciences, Inc.Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | 2026-12 |
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT07617194AusperBio Therapeutics Inc.Study of AHB-171 in Chronic Hepatitis B Participants | 2027-10-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 88 studies in Hepatitis B, Chronic with a site in Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Nucleos(t)ides analogues(NAs) is a safe and effective treatment among chronic hepatitis B(CHB) patients with excellent tolerance. Entecavir or tenofovir mono therapy has been shown to achieve inhibition of HBV replication in almost all adherent patients. However, HBsAg loss rate is low even after long-term NAs treatment. Recent studies indicated that cessation of NAs treatment could increase HBsAg clearance rate. Identifying the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance is very important.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
Drug: Stop current treatment (anti-HBV neucleos(t)ides)
Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
Drug: Keep current treatment (anti-HBV neucleos(t)ides)
Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Incidence of HBsAg clearance
The incidence of HBsAg clearance during the off-treatment period
Time frame: From baseline to the end of the fifth year after cessation of anti-HBV treatment.
Incidence of HBsAg seroconversion
The incidence of HBsAg seroconversion during the off-treatment period
Time frame: From baseline to the end of the fifth year after cessation of anti-HBV treatment.
Incidence of sustain HBV viral submission
The incidence of sustain HBV viral submission during the off-treatment period
Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.
Incidence of sustain biological response
The incidence of sustain biological response during the off-treatment period
Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.
Incidence of hepatocellular carcinoma
The incidence of hepatocellular carcinoma during the off-treatment period
Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.
Incidence of Liver failure
The incidence of Liver failure during the off-treatment period
Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2018 (actual). Primary completion is estimated for Dec 2025, 84 months after the start.
Of 46 non-industry phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 83. This study's planned 84 months is above that.
Counting every sponsor, half of 63 studies reached it within 44 months; a quarter within 30 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Humanity & Health Medical Group Limited